» Articles » PMID: 15311940

CYP51 from Trypanosoma Brucei is Obtusifoliol-specific

Overview
Journal Biochemistry
Specialty Biochemistry
Date 2004 Aug 18
PMID 15311940
Citations 51
Authors
Affiliations
Soon will be listed here.
Abstract

New isoforms of CYP51 (sterol 14alpha-demethylase), an essential enzyme in sterol biosynthesis and primary target of azole antimycotic drugs, are found in pathogenic protists, Trypanosoma brucei(TB), T. vivax, T. cruzi, and Leishmania major. The sequences share approximately 80% amino acid identity and are approximately 25% identical to sterol 14alpha-demethylases from other biological kingdoms. Differences of residues conserved throughout the rest of the CYP51 family that align with the BC-loop and helices F and G of CYP51 from Mycobacterium tuberculosis (MT)) imply possible alterations in the topology of the active site cavity of the protozoan enzymes. CYP51 and cytochrome P450 reductase (CPR) from TB were cloned, expressed in Escherichia coli, and purified. The P450 has normal spectral features (including absolute absorbance, carbon monoxide, and ligand binding spectra), is efficiently reduced by TB and rat CPR but demonstrates altered specificity in comparison with human CYP51 toward three tested azole inhibitors, and contrary to the human, Candida albicans, and MT isoforms, reveals profound substrate preference toward obtusifoliol (turnover 5.6 min(-1)). It weakly interacts with the other known CYP51 substrates; slow lanosterol conversion predominantly produces the 14alpha-carboxyaldehyde intermediate. Although obtusifoliol specificity is typical for plant isoforms of CYP51, the set of sterol biosynthetic enzymes in the protozoan genomes together with available information about sterol composition of kinetoplastid cells suggest that the substrate preference of TBCYP51 may reflect a novel sterol biosynthetic pathway in Trypanosomatidae.

Citing Articles

CYP5122A1 encodes an essential sterol C4-methyl oxidase in Leishmania donovani and determines the antileishmanial activity of antifungal azoles.

Jin Y, Basu S, Feng M, Ning Y, Munasinghe I, Joachim A Nat Commun. 2024; 15(1):9409.

PMID: 39482311 PMC: 11528044. DOI: 10.1038/s41467-024-53790-5.


Updates on Mechanisms of Cytochrome P450 Catalysis of Complex Steroid Oxidations.

Guengerich F, Tateishi Y, McCarty K, Yoshimoto F Int J Mol Sci. 2024; 25(16).

PMID: 39201706 PMC: 11354347. DOI: 10.3390/ijms25169020.


Identification of Potent and Selective Inhibitors of : Structural Insights into Sterol 14α-Demethylase as a Key Drug Target.

Hargrove T, Lamb D, Wawrzak Z, Hull M, Kelly S, Guengerich F J Med Chem. 2024; 67(9):7443-7457.

PMID: 38683753 PMC: 11089504. DOI: 10.1021/acs.jmedchem.4c00303.


Druggable Sterol Metabolizing Enzymes in Infectious Diseases: Cell Targets to Therapeutic Leads.

Nes W, Chaudhuri M, Leaver D Biomolecules. 2024; 14(3).

PMID: 38540670 PMC: 10968281. DOI: 10.3390/biom14030249.


Cytochrome P450 Enzymes as Drug Targets in Human Disease.

Guengerich F Drug Metab Dispos. 2023; 52(6):493-497.

PMID: 37793784 PMC: 11114603. DOI: 10.1124/dmd.123.001431.